Aldosterone predicts cardiovascular, renal, and metabolic disease in the general community: A 4-year follow-up

Journal of the American Heart Association

Volumn 4, Issue 12, 2015, Pages

  Buglioni, Alessia ^a,b   Cannone, Valentina ^a,b   Sangaralingham, S Jeson ^a,b   Heublein, Denise M ^a,b   Scott, Christopher G ^b   Bailey, Kent R ^b   Rodeheffer, Richard J ^b   Sarzani, Riccardo ^c,d   Burnett, John C ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d INRCA   (Italy)

Author keywords

Aldosterone; Diabetes mellitus; General community; Heart failure; Obesity

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; MINERALOCORTICOID RECEPTOR; NATRIURETIC FACTOR; NICOTINIC ACID; THIAZIDE DIURETIC AGENT; BIOLOGICAL MARKER;

AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMMUNITY CARE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; HEART FUNCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SEX; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE; ABDOMINAL OBESITY; BLOOD; ECHOCARDIOGRAPHY; FOLLOW UP; HEART FAILURE; HYPERLIPIDEMIAS; PREDICTIVE VALUE;

AGED; ALDOSTERONE; BIOMARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; KIDNEY DISEASES; MALE; OBESITY, ABDOMINAL; PREDICTIVE VALUE OF TESTS;

EID: 84991521643     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002505     Document Type: Article

References (38)

1. Messaoudi S, Gravez B, Tarjus A, Pelloux V, Ouvrard-Pascaud A, Delcayre C, Samuel J, Launay JM, Sierra-Ramos C, Alvarez de la Rosa D, Clement K, Farman N, Jaisser F. Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension. 2013;61:361-367.
2. Rocha R, Stier CT, Kifor I, Ochoa-Maya Margarita R, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878.
3. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438-3446.
4. Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K, Kaifu K, Ihara G, Fujita Y, Ugawa T, Kohno M. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 2007;50:750-755.
5. Tokuyama H, Wakino S, Hara Y, Washida N, Fujimura K, Hosoya K, Yoshioka K, Hasegawa K, Minakuchi H, Homma K, Hayashi K, Itoh H. Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury. Int J Obes (Lond). 2012;36:1062-1071.
6. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Correa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurindependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069-1078.
7. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41.
8. Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, Benjamin EJ, Vasan RS. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol. 2010;21:2143-2149.
9. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, Selhub J, D'Agostino RB Sr, Wang TJ, Vasan RS. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116:984-992.
10. Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, Bailey KR, Rodeheffer RJ, Dessi-Fulgheri P, Sarzani R, Burnett JC Jr. Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension. 2015;65:45-53.
11. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ III. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012;87:1202-1213.
12. McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, Rodeheffer RJ, Burnett JC Jr. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010;55:2140-2147.
13. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfucntion in the community. J Am Med Assoc. 2003;289:194-202.
14. Mayes D, Furuyama S, Kem DC, Nugent CA. A radioimmunoassay for plasma aldosterone. J Clin Endocrinol Metab. 1970;30:682-685.
15. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, Burnett JC Jr. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993;341:1105-1109.
16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108.
17. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-S45.
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143-3421.
19. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47:312-318.
20. Calhoun DA, Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin. 2010;28:517-527.
21. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep. 2011;13:163-172.
22. Boscaro M, Giacchetti G, Ronconi V. Visceral adipose tissue: emerging role of gluco-and mineralocorticoid hormones in the setting of cardiometabolic alterations. Ann N Y Acad Sci. 2012;1264:87-102.
23. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens. 2008;26:831-843.
24. Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V, Fabbri A, Zennaro MC, Feve B. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011;152:113-125.
25. Armani A, Cinti F, Marzolla V, Morgan J, Cranston GA, Antelmi A, Carpinelli G, Canese R, Pagotto U, Quarta C, Malorni W, Matarrese P, Marconi M, Fabbri A, Rosano G, Cinti S, Young MJ, Caprio M. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014;28:3745-3757.
26. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, Quinkler M, Hanslik G, Lang K, Hahner S, Allolio B, Meisinger C, Holle R, Beuschlein F, Bidlingmaier M, Endres S. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension. 2012;60:618-624.
27. Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids. 2014;91:54-60.
28. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis. 2010;52:401-409.
29. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensinconverting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641-2650.
30. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(suppl 1):S3-S8.
31. Herder C, Kowall B, Tabak AG, Rathmann W. The potential of novel biomarkers to improve risk prediction of type 2 diabetes. Diabetologia. 2014;57:16-29.
32. Catena C, Verheyen N, Pilz S, Kraigher-Krainer E, Tomaschitz A, Sechi LA, Pieske B. Plasma aldosterone and left ventricular diastolic function in treatment-naive patients with hypertension: tissue-Doppler imaging study. Hypertension. 2015;65:1231-1237.
33. Meyer KA, Harnack LJ, Luepker RV, Zhou X, Jacobs DR, Steffen LM. Twentytwo-year population trends in sodium and potassium consumption: the Minnesota Heart Survey. J Am Heart Assoc. 2013;2:e000478 doi: 10.1161/JAHA.113.000478.
34. St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ III, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc. 2012;87:151-160.
35. Musani SK, Vasan RS, Bidulescu A, Liu J, Xanthakis V, Sims M, Gawalapu RK, Samdarshi TE, Steffes M, Taylor HA, Fox ER. Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. Diabetes Care. 2013;36:3084-3092.
36. Pitt B. Mineralocorticoid receptor antagonists for the treatment of hypertension and the metabolic syndrome. Hypertension. 2015;65:41-42.
37. Nakagawa H, Oberwinkler H, Nikolaev VO, Gaßner B, Umbenhauer S, Wagner H, Saito Y, Baba HA, Frantz S, Kuhn M. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation. Circ Heart Fail. 2014;7:814-821.
38. McKie PM, Cataliotti A, Huntley BK, Martin FL, Olson TM, Burnett JC Jr. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol. 2009;54:1024-1032.